Metaxalone Explained

Metaxalone, sold under the brand name Skelaxin, is a muscle relaxant medication used to relax muscles and relieve pain caused by strains, sprains, and other musculoskeletal conditions.[1] Its exact mechanism of action is not known, but it may be due to general central nervous system depression. It is a moderately strong muscle relaxant, with relatively low incidence of side effects.

Common side effects include nausea, vomiting, drowsiness, and central nervous system (CNS) side effects, such as dizziness, headache, and irritability.

The metabolism of metaxalone involves enzymes CYP1A2 and CYP2C19 in the cytochrome P450 system. Because many medications are metabolized by enzymes in this system, precaution must be taken when administering it with other medications involving the P450 system to avoid interactions.[2]

Because of the potential for side effects, this drug is considered high risk in the elderly.

Pharmacokinetics

Metaxalone exhibits increased bioavailability when taken with food.[3] Specifically, in one study, compared to fasted conditions, the presence of food at the time of drug administration increased Cmax by 77.5%, AUC0-t by 23.5%, and AUC0-∞ by 15.4%.[4] Metaxalone is a substrate of CYP1A2 and CYP2C19, an inhibitor of CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A, and an inducer of CYP1A2 and CYP3A4.

Assay

A literature survey reveals very few methods are reported for the determination of metaxalone to date. Nirogi et al. reported a liquid chromatographic method coupled to tandem mass spectrometry for the quantification of metaxalone in human plasma. A stability-indicating HPLC method was introduced by P.K. Sahu et al.[5] Metaxalone has been used as an internal standard for few analytical methods.[6] [7]

External links

Notes and References

  1. Web site: Skelaxin- metaxalone tablet . DailyMed . U.S. National Library of Medicine . 27 April 2018 . 23 October 2020.
  2. US . 7378434 . Metaxalone products, method of manufacture, and method of use . Du J, Roberts RH . Takeda Pharmaceuticals USA Inc. . 27 May 2008 .
  3. Web site: Skelaxin Package Insert . https://web.archive.org/web/20100309050550/http://www.kingpharm.com/products/product_document.cfm?brand_name=Skelaxin&product_specific_name=&document_type_code=PI . 9 March 2010 . King Pharmaceuticals, Inc. .
  4. Nirogi RV, Kandikere VN, Shukla M, Mudigonda K, Shrivastava W, Datla PV . Quantification of metaxalone in human plasma by liquid chromatography coupled to tandem mass spectrometry . Journal of Analytical Toxicology . 30 . 4 . 245–251 . May 2006 . 16803662 . 10.1093/jat/30.4.245 . free .
  5. Sahu PK, Annapurna MM, Kumar SD . Development and Validation of Stability Indicating RP-HPLC Method for the Determination of Metaxalone in Bulk and its Pharmaceutical Formulations . e-Journal of Chemistry . 2011 . 8 . s1 . S439–S447 . 10.1155/2011/645710 . free .
  6. Mistri HN, Jangid AG, Pudage A, Gomes N, Sanyal M, Shrivastav P . High throughput LC-MS/MS method for simultaneous quantification of lamivudine, stavudine and nevirapine in human plasma . Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences . 853 . 1–2 . 320–332 . June 2007 . 17481969 . 10.1016/j.jchromb.2007.03.047 .
  7. Mistri HN, Jangid AG, Pudage A, Shrivastav P . HPLC-ESI-MS/MS validated method for simultaneous quantification of zopiclone and its metabolites, N-desmethyl zopiclone and zopiclone-N-oxide in human plasma . Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences . 864 . 1–2 . 137–148 . March 2008 . 18313371 . 10.1016/j.jchromb.2008.02.004 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Metaxalone".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.